<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611024</url>
  </required_header>
  <id_info>
    <org_study_id>PM1183-A-014-15</org_study_id>
    <nct_id>NCT02611024</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors</brief_title>
  <official_title>Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination
      with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD)
      of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 6, 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with selected advanced solid tumors will be divided into two groups: the PM01183 Escalation Group and the Irinotecan Escalation Group. Each group will have a different dose escalation scheme.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>48 months</time_frame>
    <description>The MTD for each group will be the lowest dose level explored during dose escalation which one third or more of evaluable patients develops DLT in Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Dose (RD)</measure>
    <time_frame>48 months</time_frame>
    <description>The RD for each groupwill be the highest dose level explored during dose escalation in which fewer than one third of evaluable patients develop DLT during Cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the curve)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of Cmax (maximum concentration)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183 1.0 mg/m2 D1 60 min i.v. infusion q3wk
Irinotecan 75 mg/m2 D1-8 90 min. i.v. infusion q3wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183 3.0 mg/m2 D1 60 min i.v. infusion q3wk
Irinotecan 15 mg/m2 D1-8 90 min. i.v. infusion q3wk</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lurbinectedin (PM01183)</intervention_name>
    <description>lurbinectedin (PM01183) 4mg vials</description>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>irinotecan 40 mg, 100 mg or 300 mg vials</description>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily signed and dated written informed consent prior to any specific-study
             procedure.

          -  Age between 18 and 70 years (both inclusive).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.

          -  Life expectancy ≥ 3 months.

          -  No more than two prior lines of cytotoxic-containing chemotherapy regimens for
             advanced disease. There is no limit for prior targeted therapy, hormonal therapy and
             immunotherapy (such as nivolumab).

          -  Histologically or cytologically confirmed diagnosis of advanced disease of any of the
             following tumor types:

               1. Glioblastoma.

               2. Soft-tissue sarcoma [excluding gastrointestinal stromal tumors (GIST)].

               3. Endometrial carcinoma.

               4. Epithelial ovarian carcinoma (including primary peritoneal disease and/or
                  fallopian tube carcinomas and/or endometrial adenocarcinomas) regardless of
                  platinum sensitivity.

               5. Mesothelioma.

               6. Gastroenteropancreatic neuroendocrine tumors (GEPNET).

               7. Small cell lung cancer (SCLC).

               8. Pancreatic adenocarcinoma.

               9. Gastric carcinoma.

              10. Colorectal carcinoma (CRC).

          -  Expansion phase: Tumor-specific cohort(s) at the RD:

               1. Measurable disease according to Response Evaluation Criteria in Solid Tumors
                  (RECIST) v.1.1.

               2. Documented disease progression per RECIST v.1.1 during or immediately after last
                  therapy according to any of the aforementioned criteria.

          -  At least three weeks since the last anticancer therapy, including investigational
             drugs and radiotherapy, and at least six weeks since nitrosoureas and mitomycin
             C(systemic).

          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before
             inclusion in the study):

               1. Platelet count ≥ 100 × 109/L, hemoglobin ≥ 9.0 g/dL and absolute neutrophil count
                  (ANC) ≥ 2.0 × 109 /L.

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × the
                  upper limit of normal(ULN), even in the presence of liver metastases.

               3. Alkaline phosphatase (ALP) ≤ 2.5 × ULN (≤ 5 × ULN if disease-related/in the case
                  of liver metastases).

               4. Total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN.

               5. International Normalized Ratio (INR) &lt; 1.5 (except if patient is on oral
                  anticoagulation therapy).

               6. Calculated creatinine clearance (CrCL) ≥ 30 mL/minute (using Cockcroft-Gault
                  formula).

               7. Creatine phosphokinase (CPK) ≤ 2.5 × ULN.

               8. Albumin ≥ 3.0 g/dL.

          -  Recovery to grade ≤ 1 or to baseline from any adverse event (AE) derived from previous
             treatment (excluding alopecia and/or cutaneous toxicity and/or peripheral neuropathy
             and/or fatigue grade ≤ 2).

        Exclusion Criteria:

          -  Concomitant diseases/conditions:

               1. History or presence of unstable angina, myocardial infarction, congestive heart
                  failure, or clinically significant valvular heart disease within the previous
                  year.

               2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing
                  treatment.

               3. Ongoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C.
                  Known Gilbert disease.

               4. Active uncontrolled infection.

               5. Known human immunodeficiency virus (HIV) or known hepatitis C virus (HCV)
                  infection or active hepatitis B.

               6. Myopathy or any clinical situation that causes significant and persistent
                  elevation of CPK (&gt; 2.5 × ULN in two different determinations performed one week
                  apart).

               7. Any past or present chronic inflammatory colon and/or liver disease, past
                  intestinal obstruction, pseudo or subocclusion or paralysis.

               8. Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or
                  cardiac effusion rapidly increasing and/or necessitating prompt local treatment
                  within seven days.

               9. Limitation of the patient's ability to comply with the treatment or follow-up
                  protocol.

              10. Any other major illness that, in the Investigator's judgment, will substantially
                  increase the risk associated with the patient's participation in this study.

          -  Prior treatment with PM01183, trabectedin (Yondelis®) or topoisomerase I inhibitors
             (irinotecan, topotecan, etc.).

          -  Prior bone marrow or stem cell transplantation, or radiation therapy in more than 35%
             of bone marrow.

          -  Known brain metastases or leptomeningeal disease involvement. Glioblastoma lesions
             (primary or locally advanced) are eligible.

          -  Women who are pregnant or breast feeding and fertile patients (men and women) who are
             not using an effective method of contraception. All patients (men and women) must
             agree to use an effective method of contraception (if applicable) up to three months
             after treatment discontinuation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pharma Mar Clinical Oncology</last_name>
    <email>clinicaltrials@pharmamar.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital -</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Cote, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Paz-Ares, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María José Flor Oncala, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lurbinectedin</keyword>
  <keyword>PM01183</keyword>
  <keyword>tumors</keyword>
  <keyword>cancer</keyword>
  <keyword>Pharma Mar</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

